Boston Partners Boosts Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Boston Partners boosted its stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 144.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,637,429 shares of the company's stock after acquiring an additional 1,556,831 shares during the period. Boston Partners owned 2.03% of Henry Schein worth $199,393,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HSIC. McGlone Suttner Wealth Management Inc. purchased a new stake in Henry Schein during the fourth quarter valued at about $39,000. Neo Ivy Capital Management bought a new position in Henry Schein in the 3rd quarter worth approximately $46,000. Covestor Ltd boosted its holdings in Henry Schein by 22.8% in the 3rd quarter. Covestor Ltd now owns 1,367 shares of the company's stock worth $102,000 after buying an additional 254 shares during the period. Benjamin F. Edwards & Company Inc. grew its stake in Henry Schein by 37.8% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,516 shares of the company's stock valued at $114,000 after buying an additional 416 shares in the last quarter. Finally, GAMMA Investing LLC bought a new stake in Henry Schein during the 4th quarter valued at $115,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of Henry Schein stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the transaction, the insider now directly owns 209,562 shares of the company's stock, valued at approximately $15,585,125.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at $5,430,462.24. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the firm's stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the sale, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. Company insiders own 1.14% of the company's stock.

Analyst Ratings Changes

HSIC has been the subject of several recent research reports. Jefferies Financial Group lifted their price target on Henry Schein from $74.00 to $81.00 and gave the company a "hold" rating in a research report on Wednesday, March 6th. Leerink Partnrs restated a "market perform" rating on shares of Henry Schein in a research report on Monday, February 26th. TheStreet raised shares of Henry Schein from a "c+" rating to a "b-" rating in a report on Monday, February 26th. SVB Leerink initiated coverage on shares of Henry Schein in a report on Monday, February 26th. They issued a "market perform" rating and a $78.00 price target for the company. Finally, UBS Group lowered their price objective on Henry Schein from $82.00 to $80.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Henry Schein currently has an average rating of "Hold" and an average target price of $81.73.

Henry Schein Price Performance

NASDAQ:HSIC traded down $0.18 during mid-day trading on Monday, reaching $73.13. The stock had a trading volume of 679,923 shares, compared to its average volume of 1,103,089. The stock has a market capitalization of $9.40 billion, a P/E ratio of 24.71, a P/E/G ratio of 1.92 and a beta of 0.87. The firm has a 50 day moving average price of $72.80 and a two-hundred day moving average price of $72.51. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.02 and a current ratio of 1.75. Henry Schein, Inc. has a one year low of $60.01 and a one year high of $82.63.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $1.10 earnings per share for the quarter, topping analysts' consensus estimates of $1.01 by $0.09. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. The firm had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.21 billion. During the same period in the previous year, the business posted $1.21 EPS. The business's quarterly revenue was up 3.7% on a year-over-year basis. As a group, analysts expect that Henry Schein, Inc. will post 5.08 earnings per share for the current year.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.